Atria Investments LLC Has $2.82 Million Position in Abbott Laboratories (ABT)
Atria Investments LLC lowered its holdings in Abbott Laboratories (NYSE:ABT) by 1.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 57,917 shares of the healthcare product maker’s stock after selling 597 shares during the period. Atria Investments LLC’s holdings in Abbott Laboratories were worth $2,815,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of ABT. State Street Corp boosted its holdings in Abbott Laboratories by 18.9% in the first quarter. State Street Corp now owns 80,499,469 shares of the healthcare product maker’s stock valued at $3,574,987,000 after purchasing an additional 12,806,535 shares during the last quarter. Boston Partners boosted its holdings in Abbott Laboratories by 5,663.7% in the first quarter. Boston Partners now owns 8,212,035 shares of the healthcare product maker’s stock valued at $364,696,000 after purchasing an additional 8,069,557 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Abbott Laboratories by 11.0% in the first quarter. Bank of New York Mellon Corp now owns 33,796,869 shares of the healthcare product maker’s stock valued at $1,500,920,000 after purchasing an additional 3,344,508 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in Abbott Laboratories by 33.8% in the first quarter. Ameriprise Financial Inc. now owns 8,823,399 shares of the healthcare product maker’s stock valued at $391,841,000 after purchasing an additional 2,231,316 shares during the last quarter. Finally, Swiss National Bank boosted its holdings in Abbott Laboratories by 45.3% in the first quarter. Swiss National Bank now owns 6,528,788 shares of the healthcare product maker’s stock valued at $289,943,000 after purchasing an additional 2,035,170 shares during the last quarter. 71.50% of the stock is owned by hedge funds and other institutional investors.
In other Abbott Laboratories news, insider Brian J. Blaser sold 15,000 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $50.00, for a total transaction of $750,000.00. Following the sale, the insider now directly owns 143,154 shares of the company’s stock, valued at $7,157,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Stephen R. Fussell sold 196,550 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $49.50, for a total value of $9,729,225.00. Following the sale, the insider now directly owns 221,488 shares in the company, valued at $10,963,656. The disclosure for this sale can be found here. Insiders have sold 218,150 shares of company stock worth $10,811,179 over the last ninety days. Company insiders own 0.76% of the company’s stock.
Shares of Abbott Laboratories (NYSE ABT) traded down 0.06% during mid-day trading on Thursday, hitting $51.86. The company had a trading volume of 1,602,954 shares. Abbott Laboratories has a 12-month low of $37.38 and a 12-month high of $52.60. The firm has a market cap of $90.10 billion, a PE ratio of 72.63 and a beta of 1.06. The firm’s 50 day moving average is $50.14 and its 200-day moving average is $47.04.
Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. The company had revenue of $6.64 billion for the quarter, compared to the consensus estimate of $6.63 billion. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The company’s quarterly revenue was up 24.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.55 earnings per share. On average, equities analysts expect that Abbott Laboratories will post $2.49 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be issued a dividend of $0.265 per share. This represents a $1.06 dividend on an annualized basis and a yield of 2.04%. The ex-dividend date of this dividend is Thursday, October 12th. Abbott Laboratories’s payout ratio is 149.30%.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/atria-investments-llc-has-2-82-million-position-in-abbott-laboratories-abt/1578511.html.
A number of research analysts recently commented on ABT shares. BidaskClub raised Abbott Laboratories from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Jefferies Group LLC reaffirmed a “buy” rating and set a $58.00 target price on shares of Abbott Laboratories in a report on Thursday, June 29th. Zacks Investment Research raised Abbott Laboratories from a “hold” rating to a “buy” rating and set a $49.00 target price on the stock in a report on Friday, May 26th. Stifel Nicolaus increased their target price on Abbott Laboratories from $49.00 to $51.00 and gave the stock a “buy” rating in a report on Wednesday, May 31st. Finally, Wells Fargo & Company reaffirmed an “outperform” rating and set a $54.00 target price (up previously from $47.50) on shares of Abbott Laboratories in a report on Friday, June 30th. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Abbott Laboratories presently has a consensus rating of “Buy” and an average target price of $52.50.
About Abbott Laboratories
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.